Very interesting. It does say the focus will be on clinical advances but the following are listed as "additional major advances"
- Combinations of different therapies that extend survival without increasing toxicity.
- A growing number of targeted therapies are offering extended survival for more patients with difficult-to-treat cancers.
It doesn't seem a strech to me that FTO might fall under these topics.
Industry news, page-37
-
- There are more pages in this discussion • 2,133 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.65 |
Change
0.000(0.00%) |
Mkt cap ! $280.3M | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.70 | $1.63 | $119.4K | 72.19K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $1.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.67 | 4879 | 2 |
View Market Depth
| Last trade - 15.01pm 30/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |